

# Mujdat Zeybel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3133816/publications.pdf>

Version: 2024-02-01

10  
papers

399  
citations

1163117

8  
h-index

1372567

10  
g-index

12  
all docs

12  
docs citations

12  
times ranked

769  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical and molecular evaluation of MEFV gene variants in the Turkish population: a study by the National Genetics Consortium. <i>Functional and Integrative Genomics</i> , 2022, 22, 291-315.	3.5	7
2	Multimiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis. <i>Advanced Science</i> , 2022, 9, e2104373.	11.2	23
3	Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients. <i>Molecular Systems Biology</i> , 2021, 17, e10459.	7.2	22
4	Evaluation of the epigenetic alterations and gene expression levels of HepG2 cells exposed to zearalenone and $\pm$ -zearalenol. <i>Toxicology Letters</i> , 2020, 326, 52-60.	0.8	21
5	The Potential Use of Metabolic Cofactors in Treatment of NAFLD. <i>Nutrients</i> , 2019, 11, 1578.	4.1	37
6	Advances in the epigenetics of fibroblast biology and fibrotic diseases. <i>Current Opinion in Pharmacology</i> , 2019, 49, 102-109.	3.5	5
7	Plasma cell-free DNA methylation: a liquid biomarker of hepatic fibrosis. <i>Gut</i> , 2018, 67, 1907-1908.	12.1	21
8	A Proof-of-Concept for Epigenetic Therapy of Tissue Fibrosis: Inhibition of Liver Fibrosis Progression by 3-Deazaneplanocin A. <i>Molecular Therapy</i> , 2017, 25, 218-231.	8.2	65
9	Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease. <i>Gut</i> , 2017, 66, 1321-1328.	12.1	172
10	Ivacaftor and symptoms of extra-oesophageal reflux in patients with cystic fibrosis and G551D mutation. <i>Journal of Cystic Fibrosis</i> , 2017, 16, 124-131.	0.7	20